Skip to content
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Loading stock detail

Preparing the latest stock view…

We're pulling the screening verdict, quote snapshot, and company context now.

Is Divi's Laboratories Ltd. Shariah Compliant? | BarakFi | BarakFi
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Home›Screener›DIVISLAB
DIVISLAB logo
DIVISLABNSE

Divi's Laboratories Ltd.

Healthcare · Large Cap · India
₹6,797.5
▼ ₹89.5 (-1.30%) today
Day Range: ₹6,726 – ₹6,855.5
Volume: 1.6 L · as of 28 May 2026, 9:20 am
Shariah Status
Requires Review
Report Credit
Opening this stock page uses 1 of your 50 monthly report credits.
Last screened 29 May 2026, 7:33 pm IST.
Methodology
AAOIFI aligned · 2026.04.2
See Full Breakdown
Requires Review
Compliance
Market Data
About
Similar Stocks
Add to Watchlist
Share
Shariah Compliance Breakdown
Debt Ratio
Interest-bearing debt compared to methodology denominator (AAOIFI: total assets). Must stay below 30%.
Disclaimer:The information on this page is for educational purposes only and does not constitute a religious ruling (fatwa) or financial advice. Shariah compliance status is derived from publicly available financial data and BarakFi's methodology mapping. Individual scholars may reach different conclusions. Always consult a qualified Islamic finance scholar and a licensed financial advisor before making investment decisions.
BarakFi
Shariah-compliant stock research for Indian equities. Educational only.
Product
ScreenerWatchlistCompare
Learn
MethodologyAbout
Legal
PrivacyDisclaimer
© 2026 BarakFi · Educational screening · Not a religious ruling or financial adviceMade in India
Threshold: 30%
Not disclosed
Borderline
Interest Income
Interest and treasury-based income as a share of business income. Must stay below 5%.
Threshold: 5%
0.0%
Pass
Non-permissible Income
Non-halal income compared to total business income. Must stay below 5%.
Threshold: 5%
Not detected
Pass
Accounts Receivable
Receivables compared to methodology denominator (AAOIFI: total assets). Must stay below 49%.
Threshold: 49%
14.9%
Pass
Business Activity
Core business lines should avoid prohibited sectors and interest-driven revenue dependence.
Allowed
Pass
Cash & Interest-bearing Assets
Cash, equivalents, and interest-bearing balances compared to total assets. Must stay below 30%.
Threshold: 30%
0.6%
Pass
Why Requires Review
Divi's Laboratories Ltd. currently screens as requires review on BarakFi. Insufficient data for: debt_ratio. Debt ratio: Total debt figure is missing from the latest reliable filing.
Market Data
Current Price
₹6,797.5
Day Range
₹6,726 – ₹6,855.5
52-Week Range
₹5,636.5 – ₹7,071.5
Volume
1.6 L
Market Cap
₹1.77 L Cr
P/E Ratio
67.5×
About Divi's Laboratories Ltd.

Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 16,543 full-time employees. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).

BarakFi combines that company context with filing-driven screening ratios, market-cap evidence, and live quote snapshots so you can review the stock through a Shariah-screening lens without losing the underlying business picture.

Index and universe context: Nifty 100 • Nifty 50 • Nifty 500.

HealthcareLarge CapIndiaNSENifty 100Nifty 50Nifty 500
Other Stocks in Healthcare
SUNPHARMA
Sun Pharmaceutical Industries Ltd.
Compliant
TORNTPHARM
Torrent Pharmaceuticals Ltd.
Not Compliant
APOLLOHOSP
Apollo Hospitals Enterprise Ltd.
Compliant
CIPLA
Cipla Ltd.
Compliant
ZYDUSLIFE
Zydus Lifesciences Ltd.
Compliant
Key Compliance Ratios
Debt RatioNot disclosed
Interest Income0.0%
Non-permissible IncomeNot detected
Receivables Ratio14.9%
Overall StatusRequires Review
Stock Information
TickerDIVISLAB
ExchangeNSE
SectorHealthcare
CountryIndia
Market Cap₹1.77 L Cr
36M Avg MCap₹1.37 L Cr
Cap SizeLarge Cap
About this Screening
This page uses an AAOIFI-aligned methodology version 2026.04.2, checking debt, interest income, non-permissible income, receivables, and balance-sheet context from the current filings dataset.

This is educational only — not a religious ruling or financial advice. Read the full methodology for threshold context and update cadence.

Read full methodology →
Track this stock
Add DIVISLAB to your watchlist so you can revisit its status after the next fundamentals sync.
Open Watchlist